-
Product Insights
Acute Lymphocytic Leukemia (ALL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Global Clinical Trials Review, 2025" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Diffuse Cutaneous Systemic Sclerosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diffuse Cutaneous Systemic Sclerosis - Global Clinical Trials Review, 2025" provides an overview of Diffuse Cutaneous Systemic Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Cutaneous Systemic Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Insomnia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Insomnia - Global Clinical Trials Review, 2025" provides an overview of Insomnia Clinical trials scenario. This report provides top line data relating to the clinical trials on Insomnia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Prostate Cancer Epidemiology Analysis and Forecast to 2033
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with...
-
Sector Analysis
Severe Asthma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This new set to update and replace the previous asthma market analysis publication, Asthma: Global Drug Forecast and Market Analysis to 2029 (December 2020, GDHC208PIDR), which covered the forecast period 2019–29. This new publication covers the severe asthma market over the forecast period of 2023-33. GlobalData estimated the total severe asthma market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain,...
-
Thematic Analysis
US Elections – Trump Tariffs (Fourth Edition) - Strategic Intelligence
This edition focuses on the policy of the new Trump administration that will have the strongest and most wide-ranging impact on the global economy, namely tariffs. This policy revolves around increases – threatened and actual – in the tariff rates levied on imports into the US. How Trump’s tariff campaign plays out will affect businesses’ US market access and profitability, along with the timing and location of investment decisions, in major industry sectors worldwide. This edition focuses on the policy...
-
Sector Analysis
Fragile X Syndrome Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2030
This report covers the US and Germany and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030. The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030. The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry,...
-
Sector Analysis
Duchenne Muscular Dystrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the DMD market through 2033. Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Dystrophin is part of a group of proteins, which together form the dystrophin-associated protein complex (DPC). These proteins form a transmembrane scaffold that is crucial for the structure of the muscle tissue, protecting muscle fibers...
-
Thematic Analysis
43rd Annual JP Morgan Healthcare Conference, January 13–16, 2025
The 43rd Annual JP Morgan Healthcare Conference took place in San Francisco, California on January 13-16, 2025. The event is the largest and most informative health care investment symposium in the industry. This year’s invitation-only conference provided key insights into the evolving strategies, pipeline advancements, and market trends shaping the biopharmaceutical industry, including acquisitions, innovative pipeline developments, and strategic shifts to navigate a rapidly changing healthcare landscape. In this report GlobalData provides an in-depth analysis of the key themes, strategic...